In Vitro Evaluation of Heparin Fractions: Old vs. New Methods

References

• Baugh R. F., Hougie C. Biochemistry of blood coagulation. Recent Advances in Blood Coagulation, L. Poller. Churchill Livingstone, London 1977; 1
   Google Scholar
• Bjork I., Lindahl U. Mechanism of the anticoagulant action of heparin. Mol. Cell Biochem. 1982; 48: 161
   PubMed Web of Science ®Google Scholar
• Pitney W. R. Heparin therapy and its laboratory control. Br. J. Haematol. 1970; 18: 499
   Google Scholar
• Teien A. N., Lie M. Heparin assay in plasma: a comparison of five clotting methods. Thromb. Res. 1975; 7: 777
   Google Scholar
• Deykin D. Monitoring heparin therapy. JAMA 1982; 247: 3136
   Google Scholar
• Simon T. L., Smith K. L. Heparin assays. Methods Hemalol. 1983; 119
   Google Scholar
• Gutman S. I., Didisheim P., Markowitz H. Two new artifacts in automated coagulation testing. Am. J. Clin. Pathol. 1980; 73: 583
   Google Scholar
• Brandt J. T., Triplett D. A. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Am. J. Clin. Pathol. 1981; 76: 530
   PubMed Web of Science ®Google Scholar
• Basu G., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New Engl. J. Med. 1972; 287: 324
   PubMed Web of Science ®Google Scholar
• Bick R. L., McClain B. J. A comparison of five activated partial thromboplastin times and the activated clotting time during heparin therapy. Thromb. Hemost. 1983; 50: 236, (Abstr. 736)
   Google Scholar
• Banez E. I., Triplett D. A., Koepke J. Laboratory monitoring of heparin therapy. The effect of different salts of heparin on the activated partial thromboplastin time. Am. J. Clin. Pathol. 1980; 74(Suppl.)530
   Google Scholar
• Poller L., Thomson J. M., Palmer M. K. Measuring partial thromboplastin time, an assessment of the performance in serial studies. J. Clin. Pathol. 1976; 35: 251
   Google Scholar
• U.S. Pharmacopeia XX. U.S. Pharmacopeial Convention, Inc., Rockville, Md, 20th revision
   Google Scholar
• Teien A. N., Abildgäard U. On the value of the activated partial thromboplastin time (APTT) in monitoring heparin therapy. Thromb. Hemost. 1976; 35: 592
   Google Scholar
• Silverglade A. Biological equivalence of beef lung and hog mucosal heparins. Curr. Ther. Res. 1975; 18: 91
   PubMed Web of Science ®Google Scholar
• Brozovic M., Bangham D. R. Standards for heparin. Heparin: Strucure, Function, and Clinical Implications, R. Bradshaw, S. Wessler. Plenum Press, New York 1975; 163
   Google Scholar
• Baltes B. J., Diamond S., D'Agostino R. Comparison of anticoagulant activity of two preparations of purified heparin. Clin. Pharmacol. Ther. 1973; 14: 287
   Google Scholar
• Gomez-Perez F. Anticoagulant activity of two commercially available heparin preparations. J. Clin Pharmacol. 1972; 12: 413
   Google Scholar
• Barrowcliffe T. W., Johnson E. A., Eggleton C. A., Thomas D. P. Anticoagulant activities of lung and mucous heparins. Thromb. Res. 1977; 12: 27
   Google Scholar
• Ofosu F. A., Cerskus A. L., Hirsh J., Smith L. M., Modi G. J., Blajchman M. A. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. Br. J. Haematol. 1984; 57: 229
   Google Scholar
• Jaques L. B., Wollin A. A modified method for the colorimetric determination of heparin. Can. J. Physiol. Pharmacol. 1967; 45: 787
   Google Scholar
• Edstrom R. D. A colorimetric method for the determination of mucopolysaccharides and other acidic polymers. Anal. Biochem. 1969; 29: 421
   Google Scholar
• Lam L. H., Silbert J. E., Rosenberg R. D. The separation of active and inactive forms of heparin. Biochem. Biophys. Res. Commun. 1976; 69: 570
   PubMed Web of Science ®Google Scholar
• Bitter T., Muir H. M. A modified uronic acid carbazole reaction. Anal. Biochem. 1962; 4: 330
   PubMed Web of Science ®Google Scholar
• Galambox J. T. The reaction of carbazole with carbohydrates. Anal. Biochem. 1967; 19: 119
   Google Scholar
• Balazs E. A., Bernsten O., Karossa J. An automated method for the determination of hexosamines. Anal. Biochem. 1965; 12: 559
   PubMed Web of Science ®Google Scholar
• Feingold D., Roden L., Forsee T. Heparin biosynthesis. Chemistry and Biology of Heparin, R. L. Lundblad, W. V. Brown, K. G. Mann, H. R. Roberts. Elsevier/North-Holland, New York 1981; 157
   Google Scholar
• Sache E., Maillard M., Bertrand H. Studies on a highly potent anticoagulant high molecular weight fraction isolated from porcine heparin. Chemistry and Biology of Heparin, R. L. Lundblad, W. V. Brown, K. G. Mann, H. R. Roberts. Elsevier/North-Holland, New York 1981; 645
   Google Scholar
• Godal H. D. The assay of heparin in thrombin systems. Scand. J. Clin. Lab. Invest. 1961; 13: 153
   PubMed Web of Science ®Google Scholar
• Barrowcliffe T. W., Johnson E. A., Eggleton C. A., Kemball-Cook G., Thomas D. P. Anticoagulant activities of high and low molecular weight fractions. Br. J. Haematol 1979; 41: 573
   PubMed Web of Science ®Google Scholar
• Lane D. A., MacGregor I. R., van Ross M., Cella G., Kakkar V. V. Molecular weight dependence of the anticoagulant properties of heparin. Intravenous and subcutaneous administration of fractionated heparins in man. Thromb. Res. 1979; 16: 651
   PubMed Web of Science ®Google Scholar
• Holmer E., Mattsson C., Nilsson S. Anticoagulant and antithrombotic effects of heparin and low-molecular-weight heparin fragments in rabbits. Thromb. Res. 1982; 25: 475
   PubMed Web of Science ®Google Scholar
• Carter C. J., Kelton J. G., Hirsh J., Gent M. Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb. Res. 1981; 21: 169
   PubMedGoogle Scholar
• McGowan F. X., Nash P. V., Bjornsson T. D. Assay-dependent kinetics of heparin: evidence for rapid in vivo activation of heparin. Br. J. Clin. Pharmacol. 1983; 16: 677
   Google Scholar
• Holmer E., Kurachi K., Soderstrom G. The molecular weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa and kallikrein by antith-rombin. Biochem. J. 1981; 193: 395
   PubMed Web of Science ®Google Scholar
• Friberger P., Egberg N., Holmer E., Hellgren M., Blömback M. Antithrombin assay—the use of human or bovine thrombin and the observation of a second heparin cofactor. Thromb. Res. 1982; 25: 433
   Google Scholar
• Cade J. F., Buchanan M. R., Boneu B., Ockelford P., Carter C. J., Cerskus A. L., Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb. Res. 1984; 35: 613
   PubMed Web of Science ®Google Scholar
• Eggleton C. A., Barrowcliffe T. W., Merton R. E., Thomas D. P. In vitro and in vivo studies of the anti-Xa activity of heparin. Thromb. Res. 1981; 24: 319
   Google Scholar
• Yin E. T., Salsgiver W. J., Tangen O. Normal human plasma contains a naturally occurring antagonist of activated factor X inhibitor (antithrombin III) activity. Thromb. Res. 1979; 15: 557
   Google Scholar
• Ofosu F. A., Modi G. J., Smith L. M., Cerskus A. L., Hirsh J., Blajchman A. Heparin sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 727
   Google Scholar
• Ofosu F. A., Modi G., Cerskus A. L., Hirsh J., Blajchman M. A. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb. Res. 1982; 28: 487
   PubMed Web of Science ®Google Scholar
• Abildgäard U., Larsen M. L. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb. Res. 1984; 35: 257
   Google Scholar
• Hojima Y., Cochrane C. G., Wiggins R. C., Austen K. F., Stevens R. L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984; 63: 1453
   PubMed Web of Science ®Google Scholar
• Tollefsen D. M., Majerus D. W., Blank M. K. Heparin cofactor II: purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 1982; 257: 2162
   PubMed Web of Science ®Google Scholar
• Ofosu F. A., Blajchman M. A., Modi G., Cerskus A. L., Hirsh J. Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin. Thromb. Res. 1981; 23: 331
   Google Scholar
• Fischer A. M., Dautzenberg M. D., Aurousseau M. H., Beguin S., Goudermand J., Hemker H. C. Comparison between the effect of Pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients. Thromb. Res. 1985; 37: 295
   Google Scholar
• Fischer A. M., Tapon-Bretaudiere J., Bros A., Josso F. Respective roles of antithrombin III and alpha 2 macroglobulin in thrombin inactivation. Thromb. Haemost. 1981; 45: 51
   Google Scholar
• Variel E. G., Boyte-Boye H., Toulemonde F., Doutremepuich C., Marsh N. A., Gaffney P. J. Heparin and a low molecular weight fraction enhances thrombolysis and by its pathway exercises a protective effect against thrombosis. Thromb. Res. 1983; 30: 219
   Google Scholar
• Bara L., Kher A., Samama M. Lower enhancement in vitro of AT III-mediated antiplasmin activity by low molecular weight heparin, PK 10169 (MW 5,000) than by unfractionated heparin. Hemo-stasis 1984; 14: 219
   Google Scholar
• Hennink W. E., Klerx J. P. A. M., van Dijk H., Feijen J. Complement inhibitory and anticoagulant activities of fractionated heparins. Thromb. Res. 1984; 36: 281
   Google Scholar
• Casu B., Johnson E. A., Mantovani M., Mulloy B., Oreste P., Peseador R., Prino G., Torro G., Zoppetti G. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates. Drug Res. 1983; 33: 135
   PubMed Web of Science ®Google Scholar
• Kecskés E., Büki K. G., Bauer P. I., Machovich R., Horváth I. Interaction of heparin with lipoproteins—role of the complex in the inactivation of thrombin and plasmin. Thromb. Haemost. 1983; 49: 138
   Google Scholar
• Eldor A., Weksler B. B. Heparin and dextran sulfate antagonize PGI2 inhibition of platelet aggregation. Thromb. Res. 1979; 16: 617
   Google Scholar
• Niewiarowski S., Rucinski B., James P., Lindahl U. Platelet antiheparin proteins and antithrombin III interact with different binding sites on heparin molecule. FEBS Lett. 1979; 102: 75
   Google Scholar
• Mastacchi R., Stanzani L., Barbanti M., Montecchi L., Bianchini P. Interaction of heparin and heparin fractions with human platelets. Thromb. Res. 1982; 28: 275
   PubMed Web of Science ®Google Scholar
• Laghi Pasini F., Pasqui A. L., Ceccatelli L., Capecchi P. L., Orrico A., Di Perri T. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vasular damage. Thromb. Res. 1984; 35: 527
   PubMed Web of Science ®Google Scholar
• Choay J., Lormeau J. C., Petitou M., Sinay P., Casu B., Oreste P., Torri G., Gatti G. Anti Xa active heparin oligosaccharide. Thromb. Res. 1980; 18: 573
   PubMed Web of Science ®Google Scholar
• Cifoneili J. A. The relationship of molecular weight, and sulfate content and distribution to anticoagulant activity of heparin preparations. Carbohydr. Res. 1974; 37: 145
   Google Scholar
• Laurent T. C., Tengblad A., Thunberg L., Hook M., Lindahl U. The molecular weight dependence of the anticoagulant activity of heparin. Biochem. J. 1978; 175: 691
   PubMed Web of Science ®Google Scholar
• Andersson L. O., Barrowclirfe T. W., Holmer E., Johnson E. A., Söderström G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb. Res. 1979; 15: 531
   PubMed Web of Science ®Google Scholar
• Graham D. T., Pomeroy A. R. Relative activities of heparin fractions obtained by gel chromatography. Thromb. Hemost. 1980; 42: 1598
   Google Scholar
• Hurst R. E., Menter J. M., West S. S., Settine J. M., Coyne E. H. Structural basis for the anticoagulant activity of heparin 1. Relationship to the number of charged groups. Biochemistry 1979; 18: 4283
   PubMedGoogle Scholar
• Hurst R. E., Poon M. C., Griffith M. J. Structure-activity relationships of heparin. Independence of heparin charge density and antithrombin-binding domains in thrombin inhibition by antithrombin and heparin cofactor II. J. Clin. Invest. 1983; 72: 1042
   PubMedGoogle Scholar
• Rosenberg R. D., Armand G., Lam L. Structure function relationships of heparin species. Proc. Natl. Acad. Sci. U.S.A. 1978; 75: 3065
   Google Scholar
• Choo I. H. F., Didisheim P., Doerge M. L., Johnson M. L., Bach M. L., Melchert L. M., Johnson W. J., Taylor W. F. Evaluation of a heparin assay method using a fluorogenic synthetic peptide substrate for thrombin. Thromb. Res. 1982; 25: 115
   Google Scholar
• Denson K. W. E., Bonnar J. The measurement of heparin. A method based on the potentiation of anti-factor Xa. Thromb. Diath. Haemorrh. 1973; 30: 471
   PubMedGoogle Scholar
• Friberger P. Properties of the “Coatest” heparin assay. Heparin. New Biochemical and Medical Aspects, I. Witt. Walter de Gruyter & Co., Berlin 1982; 117
   Google Scholar
• Handeland G. F., Abildgäard U. Assay of unfractionated and LMW heparin with chromogenic substrates: twin methods with factor Xa and thrombin. Thromb. Res. 1984; 35: 627
   Google Scholar
• Scully M., Kakkar V. V. Chromogenic Substrates. Churchill Livingstone, EdinburghScotland 1978
   Google Scholar
• Fareed J., Walenga J. M., Messmore H. L., Bermes E. W., Jr. Synthetic substrates in hemostatic testing. CRC Crit. Rev. Lab. Sci. 1983; 19: 71
   Web of Science ®Google Scholar
• Messmore H. L., Fareed J., Kniffin J., Squillaci G., Walenga J. Synthetic substrate assays of the coagulation enzymes and their inhibitors. Comparison with clotting and immunological methods for clinical and experimental usage. Ann. N. Y. Acad. Sci. 1981; 370: 787
   Google Scholar
• Odegard O. R., Abildgärd U., Lie M. Antifactor Xa measured with amidolytic methods. Haemostasis 1976; 5: 265
   Google Scholar
• Van Wijk E. M., Kahle I. H., Wiebosch M., ten Cate J. W. Optimization of a mechanized amidolytic factor X assay; influence of reaction conditions and reagents. Clin. Chem. 1981; 27: 918
   Google Scholar
• Michaud A., Aiach M. Application des substrats chromogenès à la surveillance biologique de l'héparinotheraphie. Pharmacol. Biol. 1982; 16: 29
   Google Scholar
• Kapke G. F., Feld R. D., Witte D. L., Owen W. G. Esterolytic method for determination of heparin in plasma. Clin. Chem. 1981; 27: 526
   Google Scholar
• Larsen M. L., Abildgäard U., Teien A. N., Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb. Res. 1978; 13: 285
   Google Scholar
• Mitchell G. A., Garginlo R. J., Huseby R. M., Lawson D. E., Pochron S. P., Sehuanes J. A. Assay for plasma heparin using a synthetic peptide substrate for thrombin. Introduction of the fluorophore, isophthalic acid, dimethyl ester. Thromb. Res. 1978; 13: 47
   PubMed Web of Science ®Google Scholar
• Teien A. N., Lie M., Abildgäard U. Assay of heparin in plasma using chromogenic substrate for activated factor X. Thromb. Res. 1976; 8: 413
   PubMed Web of Science ®Google Scholar
• Bartl K., Dorsch E., Lill H., Ziegenhorn J. Determination of the biological activity of heparin by use of a chromogenic substrate. Thromb. Haemost. 1979; 42: 1446
   Google Scholar
• Aiach M., Michaud A., Capron L., Fiessinger J. N. Determination of factor X and heparin with chromogenic substrate. Acta Chir. Scand. 1982; 509(Suppl.)109
   Google Scholar
• Brown J. E., Baugh R. F., Hougie C. The inhibition of the intrinsic generation of activated factor X by heparin and hirudin. Thromb. Res. 1980; 17: 267
   PubMed Web of Science ®Google Scholar
• Ofosu F., Blajchman M. A., Hirsh J. The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. Thromb. Res. 1980; 20: 391
   PubMed Web of Science ®Google Scholar
• Kakkar V. V. Prevention of postoperative venous thromboembolism by a new low molecular weight heparin fraction. Nouv. Rev. Fr. Hematol. 1984; 26: 277
   PubMedGoogle Scholar
• Kakkar V. V., Djazaeri B., Fok J., Fletcher M., Scully M. F., Westwick J. Low-molecularweight heparin and prevention of postoperative deep vein thrombosis. Br. Med. J. 1982; 284: 375
   PubMed Web of Science ®Google Scholar
• Schmitz-Heuber U., Asbeck F., van de Loo J. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. II. Effects of a heparin analogue. Thromb. Haemosti. 1981; 46: 617
   Google Scholar
• Walenga J. M., Bara L., Samama M. M., Fareed J. Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Semin. Thromb. Hemost. 1985; 11(2)104
   Google Scholar
• Walenga J. M., Fareed J., Messmore H. L. Newer avenues in the monitoring of antithrombotic therapy: the role of automation. Semin. Thromb. Hemost. 1983; 9: 346
   Google Scholar
• Yin E. T., Wessler S., Butler J. V. Plasma heparin: a unique, practical submicrogram-sensitive assay. J. Lab. Clin. Med. 1973; 81: 298
   PubMed Web of Science ®Google Scholar
• Sturzebecher J., Markwardt F., Wagner G., Boigt B. Are synthetic inhibitors able to improve factor Xa assays using peptide substrates?. Thromb. Res. 1982; 26: 221
   Google Scholar
• Hoppensteadt D., Fareed J., Walenga J. M., Emanuele R. M. Validity of serine protease inhibition tests in the in vitro and in vivo assessment of the action of heparin and its fractions. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1984; 43: 606
   Google Scholar
• Ockelford P. A., Carter C. J., Mitchell L., Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra low molecular weight fraction. Thromb. Res. 1982; 28: 401
   PubMed Web of Science ®Google Scholar
• Van Mourik J. A. The significance of fibrinopeptide A (FPA) in the diagnosis of low-grade intravascular coagulation and venous thromboembolism. Haematologia (Pavia) 1981; 66: 259
   Google Scholar
• Mombelli G., Roux A., Haeberli A., Straub P. W. Comparison of 125I fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982; 60: 381
   Google Scholar
• Peuscher F. W., van Aken W. G., Flier O. T., Stoerman-van Dalen E. A., Cremer-Goote T. M., van Mourik J. A. Effect of anticoagulant treatment measured by fibrinopeptide A (FPA) in patients with venous thromboembolism. Thromb. Res. 1980; 18: 33
   Google Scholar
• Yudelman I., Greenberg J. Factors affecting fibrinopcptide-A levels in patients with venous thromboembolism during anticoagulant therapy. Blood 1982; 49: 787
   Google Scholar
• Emanuele R. M., Fareed J., Hoppensteadt D., Walenga J. M. Development of fibrinopeptide A generation tests in the evaluation and the monitoring of the action of heparin and its low molecular weight fractions. Semin. Thromb. Hemost. 1984; 10: 243
   Google Scholar
• Johnson P. C., Ware J. A., Cliveden P. B., Smith M., Dvorah A. M., Salzman E. W. Measurement of ionized calcium in blood platelets with the photo protein aequorin: comparison with Quin Z, in press
   Google Scholar
• Yin E. T., personal communication
   Google Scholar
• Obzanky D. M., Pierson-Perry J. F., Mizzer J. P. Development and analytic performance of an automated assay for effective plasma heparin activity. Clin. Chem. 1985; 31(6)977
   Google Scholar